In a randomized phase IIb trial, trastuzumab was combined with E75 and granulocyte–macrophage colony-stimulating factor (GM-CSF) in 275 patients with low expressing HER2 BC at a high risk of recurrence. The gene discussed is CSF2; the disease is breast cancer.